Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral ...

2 September 2026 · By · Wire by Fusion42

Published

2 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 3 September 2026 · Fusion42 review

Scholar Rock has received FDA Fast Track and Orphan Drug designations for apitegromab, a treatment targeting facioscapulohumeral muscular dystrophy (FSHD), and has begun participant dosing in the Phase 2 FORGE trial.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 2 Sep 2026 and 3 Sep 2026.

◆ ◆ The Wire takeaway

You can accelerate development and market access plans now that apitegromab's fast track status reduces FDA review time and supports earlier engagement. This is a clear green light to prioritise trial recruitment and investor discussions around orphan drug benefits.

◆ Coverage

2 sources · first reported 2 Sep 2026 · latest 3 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-fast-trackorphan-drugphase-2-trialfs hdneuromuscular-disease